GE HealthCare (GEHC) is sharply lower after posting Q1 2026 earnings that came in below adjusted EPS expectations while also lowering full-year 2026 guidance. The guidance reset is the main catalyst for the outsized move, with management describing margin pressure from tariffs and inflation and additional disruption tied to supplier issues, including a PDX supplier recall that affected profitability in the quarter. (marketbeat.com)

In its updated outlook, GE HealthCare reduced full-year adjusted EPS to a range of $4.80–$5.00 and lowered expected free cash flow to about $1.6 billion, after citing higher costs and operational disruption. While demand trends were characterized as healthy, the market is repricing the stock on the view that near-term margin recovery will be harder than previously assumed. (marketbeat.com)

Investors are likely to focus on whether cost and supply-chain pressures prove temporary or persist into the next quarter, and how quickly the company can stabilize profitability as pricing, mix, and productivity initiatives work through results. Additional scrutiny will center on segment-level performance and any signs that tariffs/commodity inflation continue to compress margins despite steady revenue trends. (fool.com)